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Abstract This cost-effectiveness analysis was conducted from the patient’s perspective alongside a randomized controlled trial
comparing corifollitropin alfa with follitropin beta for a single stimulation cycle. Only unit costs paid by patients are included in this
analysis. The incremental cost-effectiveness ratio was calculated. One-way sensitivity analysis and probabilistic sensitivity analysis
(PSA) were also performed. Baseline characteristics (except for the number of follicles and frozen embryos), treatment outcomes and
complications were similar in the two groups. The live birth rate was comparable between the two groups, but the mean total cost
per patient was higher for the corifollitropin alfa strategy (€4293) compared with the follitropin beta strategy (€4086). Costs per live
birth were €13,726 and €12,511, respectively. The difference in effect between corifollitropin alfa and collitropin beta was three
fewer live births, and the difference in costs was €24,048. The probability of live birth after the first and second embryo transfers and
the proportion of patients who had no more frozen embryos available after non-achievement of live birth in the first or second
transfer influenced the comparative cost-effectiveness of the two strategies. PSA showed that a corifollitropin alfa strategy would be
rejected in up to 27.4% of scenarios. Follitropin beta 300 IU/day was more cost-effective than corifollitropin alfa 150 μg in women
aged 35–42 years weighing ≥50 kg undergoing in-vitro fertilzation/intracytoplasmic sperm injection.
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Ovarian stimulation with gonadotropins is an essential step
in each cycle of in-vitro fertilization (IVF)/intracytoplasmic
sperm injection (ICSI). Corifollitropin alfa has been devel-
oped recently to overcome issues with the short half-life and
rapid metabolic clearance of traditional agents (including
human menopausal gonadotropins and recombinant follicle-
stimulating hormone). The prolonged activity of
corifollitropin alfa, which requires only one dose over 7
days, could reduce the dropout rate and increase the success
of assisted reproductive technologies (ART) (Verberg et al.,
2008).
Several randomized controlled trials (RCT) and meta-
analyses show that there is no significant difference in
fertility, pregnancy and obstetric outcomes between women
who underwent ovarian stimulation with corifollitropin alfa
compared with follitropin beta, both in Western populations
and Asian patients aged ≥35–42 years and weighing ≥50 kg
(Boostanfar et al., 2015; Corifollitropin Alfa Dose-finding
Study, 2008; Corifollitropin Alfa Ensure Study, 2010; Devroey
et al., 2009; Griesinger et al., 2016a, 2016b; Vuong et al.,
2017).
The cost per cycle of ovarian stimulation was determined
based on data from the PURSUE study, which was conducted
in Spain (a high-income country) and only included direct
costs associated with the stimulation phase (Barrenetxea et
al., 2018). However, the literature shows that there is
currently great diversity in the IVF funding and reimburse-
ment policies within Europe, the USA, Australia and New
Zealand (Chambers et al., 2009, 2012; Connolly et al.,
2010), while patients in low- or middle-income countries
have to self-fund infertility treatments (Dyer and Patel,
2012). Moreover, the direct non-medical costs and indirect
costs of infertility treatment strategies, not always reported
or discussed in patients’ treatment decisions, represent
approximately 45–52% of the total treatment cost (Le et al.,
2018). Therefore, the findings of this study will provide
evidence on the cost-effectiveness of corifollitropin alfa
versus follitropin beta from the patient's perspective where
ART treatment is not publicly funded.
As far as is known, this is the first cost-effectiveness
analysis (CEA) to be conducted from the patient’s perspec-
tive and used data from an RCT, the Asian PURSUE study
(Vuong et al., 2017), with follow-up until delivery or until no
more embryos remained.Figure 1 Decision analytic model for economic evaluation of
corifollitropin alfa (Elonva) compared with follitropin beta (rec-
FSH). ET, embryo transfer; fET(+), fresh embryo transfer; fET
(-), fresh embryo tranfer skipped; FET1, first frozen embryo
transfer; FET2, second frozen embryo transfer; FET3, third
frozen embryo transfer; LB(+), live birth; LBe(-), no live birth
but still have embryo(s); LBn(-), no live birth and no more
embryos.Materials and methods
Study design, participants and treatments
This CEA was based on data from patients treated with
corifollitropin alfa compared with follitropin beta (standard
treatment) in a single-centre RCT in Ho Chi Minh City,
Vietnam (Ethical Approval No.: 03/15/ĐĐ-BVMĐ;NCT02466204) (Vuong et al., 2017). All patients provided
written informed consent before enrolment in the RCT. Full
study details and treatment outcomes have been reported
previously (Vuong et al., 2017).
In the decision analytic model, it is assumed that all
patients who fulfilled the inclusion criteria were randomized
to undergo ovarian stimulation using a gonadotrophin-
releasing hormone (GnRH) antagonist protocol with a single
dose of corifollitropin alfa 150 μg on Day 2 or 3 of the
menstrual cycle, or follitropin beta (recombinant FSH) 300
IU/day for 7 days starting on Day 2 or 3 of the menstrual
cycle.
From Day 8 of stimulation, participants in the two groups
could be continued with a daily subcutaneous dose of
follitropin beta (maximum 300 IU/day) up to the day before
administration of human chorionic gonadotrophin or GnRH
agonist. Oocyte retrieval followed by ICSI was performed
~34–36 h later according to the study site’s clinical practice
regulations. Two or three embryos were transferred 3 days
after oocyte retrieval.
Patients who received initial therapy with corifollitropin
alfa experienced fresh embryo transfer [fET(+)] (n=195) or
skipped the fresh embryo transfer [fET(-)] (n=61). Among
patients who underwent fET(+) (n=134), there were 32 live
births [LB(+)], 67 treatment failures with no more embryos
30 LD Khoa et al.[LBn(-)], and 35 treatment failures with remaining embryo
(s) [LBe(-)]. Patients in the fET(-) group and LBe(-) group
experienced first frozen embryo transfer (FET1) (n=
35+61=96). Of these, there were 22 LB(+), 59 LBn(-) and
15 LBe(-). These patterns were repeated at second and
third frozen embryo transfer (FET2 and FET3). A similar
model was used in patients randomized to follitropin beta,
with one fresh embryo transfer and two frozen embryo
transfers (Figure 1). Rates of maternal and fetal outcomes
after one completed cycle of ICSI were monitored for 2
years after randomization of patients in the PURSUE
study.
Although treatment outcomes were similar in the two
treatment groups, Health Technology Assessment guide-
lines suggest that a CEA should be conducted for assessment
of effectiveness rather than efficacy (Briggs and O’Brien,
2001). Data for the CEA were collected after completion of
the RCT. A course of treatment was defined as from the
start of IVF-related treatment to delivery or use of all
embryos. Direct medical costs were calculated based on
2016 prices, and the resource use data were extracted from
patients’ medical records and the 2016 financial and
activity reports (Table S1, see online supplementary
material). Direct non-medical costs and indirect costs
were determined retrospectively by telephone interviews
with each patient (Tai et al., 2016). Questionnaire
responses were then converted into direct non-medical
costs (travel costs, accommodation costs) and indirect costs
(opportunity cost). Travel expenses were calculated by
multiplying the distance, number of visits and fuel priceTable 1 Clinical parameters after one completed cycle of in-vitro
Corifollitropin
alfa
(n=195)
Follitropin
beta
(n=199)
Examination, n 4.71 (0.67) 5.79 (0.63)
Duration of stimulation, days 9.88 (1.52) 8.99 (1.22)
Ultrasound, n 2.71 (0.67) 3.79 (0.63)
Additional dose, IU 610.26 (494.87) 603.02
(355.46)
Oocytes retrieved, n 11.55 (5.81) 10.88 (5.80)
Fertility outcomes
Total fresh ET cycles, n (%) 134 (68.7) 145 (72.9)
Total FET cycles, n (%) 111 (56.9) 106 (53.3)
Embryos transferred, n 2.24 (0.72) 2.27 (0.61)
Good embryos transferred, n 1.75 (0.83) 1.89 (0.74)
Average number of ETs 1.23 (0.53) 1.21 (0.44)
Live birth, n (%) 47 (24.6) 51 (25.6)
Singleton 33 (17.3) 42 (21.1)
Twins 14 (7.3) 9 (4.5)
Moderate/severe OHSS, n (%) 2 (1.0) 1 (0.5)
Delivery in weeks, n (%)
b24 1 (0.5) 0 (0.0)
24 to b32 0 (0.0) 1 (0.5)
32 to b37 5 (2.6) 5 (2.5)
≥37 42 (21.5) 45 (22.6)
CI, confidence interval; ET, embryo transfer; FET, frozen embryo transf
Values are mean (standard deviation) or n of patients (%).based on the mode of transportation, while accommodation
costs were determined by the duration of stay multiplied by
the per-night cost. Opportunity cost (lost income) was
estimated based on the number of visits, duration of visits
and patient’s income (Table S1, see online supplementary
material). The costs [initially collected in Vietnamese Dong
(VND)] were converted to 2016€ at the exchange rate of
24,395 VND to 1€ (Van, 2016). Costs and outcomes were not
discounted or adjusted for inflation as prices were
unchanged over the 1-year timeframe of data collection.
The main effectiveness outcome measure in this analysis
was the live birth rate.
Data were input into Excel (Microsoft Corp., Redmond,
WA, USA), then exported to R Version 3.3.1 for analysis.
Mean and standard deviation values were used to summarize
continuous variables, while frequencies and percentages
were used for categorical variables; 95% confidence interval
values were also reported.
Fisher’s exact test and Student’s t-test were used to
assess between-group differences in non-continuous and
continuous variables, respectively. The incremental cost-
effectiveness ratio (ICER) was calculated to compare the
cost-effectiveness of corifollitropin alfa with follitropin
beta. P-values b0.05 were considered to indicate statistical
significance.
One-way sensitivity analysis (OSA) and probabilistic
sensitivity analysis (PSA) were used in Excel 2013 to test
the sensitivity of ICER to changes in each clinical and cost
parameter. OSA was performed using a Tornado diagram
based on the assumption that each factor varied from itsfertilization/intracytoplasmic sperm injection.
Between-group
difference (95% CI)
Risk ratio for corifollitropin alfa
versus follitropin beta (95% CI)
P-
value
1.08 (-1.21 to -0.96) b0.001
0.89 (0.61 to 1.16) b0.001
1.08 (-1.21 to -0.96) b0.001
7.24 (-78.28 to 92.76) 0.868
0.67 (-0.48 to 1.82) 0.250
-4.2 (-13.6 to 5.3) 0.94 (0.83 to 1.07) 0.365
3.6 (-6.7 to 14.0) 1.07 (0.89 to 1.28) 0.466
-0.03 (-0.17 to 0.10) 0.616
-0.06 (-0.30 to 0.02) 0.077
0.02 (-0.08 to 0.12) 0.701
-1.0 (-10.6 to 7.5) 0.93 (0.65 to 1.31) 0.815
-3.8 (-12.4 to 4.1) 0.80 (0.53 to 1.21) 0.353
-2.8 (-2.5 to 7.8) 1.59 (0.70 to 3.58) 0.363
0.5 (-1.0 to 2.7) 2.04 (0.19 to 22.33) 0.550
0.5 (-1.0 to 2.0) - 0.992
-0.5 (-2.0 to 1.0) - 0.999
0.1 (-3.2 to 3.2) 1.02 (0.30 to 3.47) 0.974
-0.9 (-9.8 to 7.6) 0.95 (0.66 to 1.38) 0.797
er; OHSS, ovarian hyperstimulation syndrome.
Table 2 Estimated cost data for one completed in-vitro fertilization/intracytoplasmic sperm injection cycle per couple.a
Average cost per couple (€) Absolute between-group difference (95%
CI)
P-
valueb
Corifollitropin alfa (n=
195)
Follitropin beta (n=
199)
Direct medical costs 3836.2 (839.5) 3574.9 (816.8) 261.3 (97.2 to 425.4) 0.002
Examination 26.6 (6.6) 37.3 (6.2) -10.7 (-12.0 to -9.4)
Ultrasound 22.2 (5.5) 31.1 (5.2) -8.9 (10.0 to -7.9)
Screening test 164.0 164.0 0.0
Stimulation drug 1361.1 (213.6) 1136.3 (182.7) 224.8 (185.4 to 264.2)
Luteal support drug 151.7 (97.5) 110.4 (80.6) 41.3 (23.5 to 59.0)
IVF/ICSI 1188.8 1188.8 0.0
Embryo freezing 270.8 (204.5) 257.5 (196.0) 13.3 (-26.4 to 53.0)
Embryo thawing 198.3 (239.7) 190.8 (234.0) 7.5 (-39.4 to 54.4)
Complications 10.1 (56.8) 14.8 (75.4) -4.7 (-18.0 to 8.5)
Drug during
pregnancy
67.8 (97.3) 66.4 (96.7) 1.4 (-17.9 to 20.6)
Test during
pregnancy
141.3 (202.6) 138.4 (201.6) 2.8 (-37.2 to 42.9)
Delivery 233.5 (351.3) 238.9 (352.7) -5.4 (-75.1 to 64.3)
Direct non-medical
costs
257.9 (267.6) 252.0 (261.9) 5.9(-46.5 to 58.4) 0.825
Travel 40.4 (80.2) 41.9 (79.5) -1.5 (-17.4 to 14.3)
Accommodation 217.6 (277.7) 210.1 (272.1) 7.5 (-47.0 to 61.9)
Indirect costs 199.6 (293.3) 259.6 (448.1) -60.1 (-135.0 to 14.9) 0.116
Opportunity 199.6 (293.3) 259.6 (448.1) -60.1 (-135.0 to 14.9)
Total cost 4293.7 (1103.6) 4086.5 (1103.5) 207.2 (-11.5 to 425.8) 0.063
CI, confidence interval; ICSI, intracytoplasmic sperm injection; IVF, in-vitro fertilization.
Values are mean (standard deviation).
Table 3 Estimated cost data per couple following fresh embryo transfer and frozen embryo transfer.
Average cost per couple (€)
Corifollitropin alfa (n=195) Follitropin beta (n=199)
Fresh embryo transfer
Direct medical costs 3836.2 (839.50) 3574.88 (816.76)
Direct non-medical costs 282.33 (287.25) 282.92 (305.03)
Indirect costs 199.58 (293.32) 259.63 (448.10)
Total cost 4318.08 (1111.82) 4117.43 (1055.33)
First frozen embryo transfer
Direct medical costs 4224.6 (768.91) 3971.03 (715.86)
Direct non-medical costs 352.3 (378.54) 310.92 (322.61)
Indirect costs 228.03 (345.55) 229.88 (260.50)
Total cost 4804.97 (1106.15) 4511.83 (932.22)
Second frozen embryo transfer
Direct medical costs 4764.84 (814.66) 4318.72 (599.65)
Direct non-medical costs 321.77 (319.96) 264.17 (255.84)
Indirect costs 300.96 (456.58) 210.35 (238.16)
Total cost 5387.57 (1185.71) 4793.24 (825.08)
Third frozen embryo transfer
Direct medical costs 4730.29 (557.72)
Direct non-medical costs 607.28 (277.42)
Indirect costs 92.23 (75.84)
Total cost 5429.81 (483.28)
Values are mean (standard deviation).
Table 4 Incremental cost-effectiveness ratio of both strategies at various embryo transfer stages.
Subgroup Corifollitropin alfa Follitropin beta ΔC or ΔE ICER (ΔC/ΔE)
Fresh ET n=134 n=145
Total cost 842,026 819,369 22,657 -11,328
Live birth 32 34 -2
Mean cost per live birth 26,313 24,099
FET1 n=96 n=92
Total cost 442,057 415,088 26,969 -5393
Live birth 22 27 -5
Mean cost per live birth 20,093 15,374
FET2 n=15 n=14
Total cost 80,814 67,105 13,709 4569
Live birth 6 3 3
Mean cost per live birth 13,469 22,368
FET3 n=4 NA
Total cost 21,719 NA NA NA
Live birth 1 NA NA
Mean cost per live birth 21,719 NA
One completed cycle
Total cost 837,267 813,219 24,048 -8016
Live birth 61 64 -3
Mean cost per live birth 13,726 12,511
Fresh ET, fresh embryo transfer; FET1, first frozen embryo transfer; FET2, second frozen embryo transfer; FET3, third frozen embryo transfer;
ΔC, incremental cost; ΔE, incremental effectiveness; ICER, incremental cost-effectiveness ratio.
32 LD Khoa et al.base-case value by ±10% while other factors were un-
changed. The results indicate the range of ICER based on a
change to a single variable. A larger range of ICER reflects
more sensitive factors. PSA with Monte Carlo simulation
(using 1000 resamples) was performed to address theFigure 2 Tornado diagram of one-way sensitivity analysis of th
parameter: base-case value ± 10%). a, ICER increases 4-fold when th
variable decreases by 10%; c, ICER decreases 4.4-fold when the v
variable decreases by 10%; e, ICER decreases 5.7-fold when the varia
increases by 10%; g, ICER decreases 13-fold when the variable inc
decreases by 10%.uncertainty around the mean estimates of incremental
costs and effects. A cost-effectiveness acceptability curve
was generated to represent the probability that the
corifollitropin alfa strategy was cost-effective at a specific
willingness-to-pay (WTP) threshold.e incremental cost-effectiveness ratio (ICER) (range of input
e variable increases by 10%; b, ICER decreases 4.4-fold when the
ariable increases by 10%; d, ICER decreases 5.9-fold when the
ble decreases by 10%; f, ICER decreases 9-fold when the variable
reases by 10%; h, ICER decreases 15.6-fold when the variable
Results
From 19 June 2015 to 10 August 2016, 400 infertile couples
were assigned at random to receive corifollitropin alfa or
follitropin beta (n=200 in each treatment group). Baseline
characteristics (except for the number of follicles and frozen
embryos), treatment outcomes and complications were
similar in both groups (Table 1). Cost data were missing for
six patients: four patients could not be contacted and two
refused to provide data. As such, 394 couples (195 in the
corifollitropin alfa group and 199 in the follitropin beta
group; 98.5% of the total study sample) were included in the
CEA. Effectiveness data were available for all 400 patients.
The live birth rate was comparable between the two
groups and the mean total cost per patient was not
significantly different [corifollitropin alfa €4293 versus
follitropin beta €4086; P=0.063) (Table 2). Most direct
medical costs were higher in the corifollitropin alfa group,
while the mean indirect costs and direct non-medical costs
associated with the corifollitropin alfa strategy were similar
to those for the follitropin beta strategy (Table 2). Table 3
depicts the estimated cost data per couple for fresh embryo
transfer and frozen embryo transfer, and Table 4 reveals
ICER of both strategies at the various embryo transfer
stages. The total cost was higher for the corifollitropin alfa
group compared with the follitropin beta group.
Cost per live birth was €13,726 with corifollitropin alfa
compared with €12,511 with follitropin beta. The difference
in effect between corifollitropin alfa and collitropin betaFigure 3 Probabilistic sensitivity analysis (PSA) scatter plots show
(IC)] and live birth rate as a percentage [incremental effectiveness (
bootstrapping 1000 trials. (I) North-east quadrant: trials in which th
follitropin beta strategy at higher cost [positive incremental cost-eff
which the corifollitropin alfa strategy had greater effectiveness t
values). (III) South-west quadrant: trials in which the corifollitropin
strategy and lower cost (positive ICER values). (IV) North-west quad
effectiveness than the follitropin beta strategy and higher cost (negwas three fewer live births, and the difference in costs was
€24,048.
ICER varied four- to 15-fold in response to changes in
several parameters (Figure 2). Of these, the probability of
live birth after the first and second embryo transfers, and
the proportion of patients who had no more frozen
embryos available after non-achievement of live birth in
the first or second transfers had the greatest influence on
ICER. Other factors (e.g. accommodation, stimulation
drug and opportunity costs) modified ICER to a lesser
extent.
Figure 3 illustrates the incremental cost-effectiveness
plane for the cost and effectiveness data bootstrapped from
the Asian PURSUE study. PSA scatter plots represent
uncertainty in ICER estimates on the incremental cost-
effectiveness plane divided into four quadrants: north-east
quadrant (I) with higher costs and higher effectiveness;
south-east quadrant (II) with lower costs and higher
effectiveness; south-west quadrant (III) with lower costs
and lower effectiveness; and north-west quadrant (IV) with
higher costs and lower effectiveness (Black, 1990). Approx-
imately 26.1% of scenarios were in Quadrant I, 20.4% were in
Quadrant II, 26.1% were in Quadrant III and 27.4% were in
Quadrant IV (Figure 3).
Figure 4 shows that, at a WTP threshold of €1950 (GDP per
capita in 2016) for an additional live birth, there is 22.1%
chance that corifollitropin alfa is cost-effective. At a WTP
threshold of €12,500 (cost per live birth in follitropin beta
group) and €13,700 (cost per live birth in corifollitropin alfaing the mean differences in costs per patient [incremental cost
IE)]. Note: the cost-effectiveness plane shows the PSA based on
e corifollitropin alfa strategy had greater effectiveness than the
ectiveness ratio (ICER) values]. (II) South-east quadrant: trials in
han the follitropin beta strategy at lower cost (negative ICER
alfa strategy had lower effectiveness than the follitropin beta
rant: trials in which the corifollitropin alfa strategy had lower
ative ICER values).
Figure 4 Cost-effectiveness acceptability curves for corifollitropin alfa strategy versus follitropin beta strategy.
34 LD Khoa et al.group), the probabilities of being cost-effective are 29.4%
and 30.3%, respectively. The probability that the
corifollitropin alfa strategy is cost-effective is approxi-
mately 38.6% at a WTP threshold of €27,035 EUR (approx-
imately 13.8 times higher than GDP per capita), with little
change in probability as the WTP threshold increased
further.Discussion
The results of this CEA, conducted from the patient’s
perspective in conjunction with an RCT (Vuong et al.,
2017), showed that a corifollitropin-based strategy for
ovarian stimulation in IVS/ICSI was not cost-effective in
Vietnam compared with a strategy based on follitropin beta.
It is important to note that Vietnam is classified as a low–
middle income country and there has been a lack of financial
support from the public and private sectors for ART. ICER
was most sensitive to changes in the live birth rate after first
and second embryo transfers, and the proportion of patients
who had no more frozen embryos available after non-
achievment of live birth in the first or second transfers.
Overall, the probability of corifollitropin alfa being cost-
effective in the population and conditions of the analysis was
only 20.4%.
The association between the patient-centred CEA and the
RCT (Vuong et al., 2017) may have some advantages when
using advanced analysis methods (e.g. OSA, PSA). Firstly, alloutcomes in the RCT closely reflected daily practice, and
RCT data provide the strongest empirical evidence of
comparative treatment efficacy. The most important out-
come for patients undergoing IVF/ICSI is the cumulative live
birth rate (meaning they get to take a new baby home),
rather than the time to success (Romundstad et al., 2015).
Secondly, costing data in this analysis included indirect, as
well as direct, costs. The indirect costs of infertility
treatment strategies are often neglected or unexpected,
and might influence a patient’s decision about proceeding
with treatment. Furthermore, useful information was ob-
tained about which factors had the greatest influence on
ICER.
Despite these advantages, a number of limitations need
to be considered when interpreting these data. Due to the
nature of cost data collected from the secondary sources and
telephone interviews, there is potential for information
recall bias (although the CEA was conducted as soon as
possible after completion of the RCT). In addition, the RCT
on which this analysis was based was conducted in a private
hospital where the costs and service prices are much higher
than in public facilities. Therefore, cost adjustments would
be necessary when applying this model to data from patients
treated in government-funded hospitals. Similarly, the data
may not be applicable to healthcare systems in other
countries.
The finding that the cost per live birth for an ovarian
stimulation strategy based on corifollitropin alfa treatment
was higher than that for follitropin-beta-based treatment
(€13,726 versus €12,511, respectively) differs from a
previous cost-minimization analysis (CMA) of the two
approaches (Barrenetxea et al., 2018). In addition to a
difference in design (CMA versus CEA), the other study was
conducted in a different setting (Spain; a high-income
country) and did not include direct non-medical and indirect
cost data. Furthermore, total costs in the Spanish study were
considered in both the private and public sectors, whereas
the present data were collected from one single private IVF
centre. In addition, OSA and PSA were performed in this
study to help understand the data, rather than CEA alone.
Although statistically total costs were higher in the
corifollitropin alfa group, values were numerically higher
with corifollitropin alfa versus follitropin beta. Costs for
stimulation drugs and luteal support agents are the main
parameters that contributed to higher direct medical costs
with corifollitropin alfa compared with follitropin beta
(Table 2). In contrast, examination and ultrasound costs
were lower in the corifollitropin alfa group; this may have
been because fewer patient visits are needed, as a single
injection of corifollitropin alfa can replace 7 days of
gonadotropin treatment with follitropin beta.
In this analysis, indirect non-medical costs (e.g. travel,
accommodation) and indirect costs (e.g. income lost) varied
between individuals. Patients may have stayed at more
expensive hotels, taken less expensive forms of transport, or
simply had a lower income. However, direct non-medical
and indirect costs did not differ significantly between the
two groups (Table 2).
OSA was performed using a Tornado diagram based on the
assumption that each factor varied from its base-case value
by ±10% while other factors were unchanged. The results
indicate the range of ICER based on a change to a single
variable. Greater range in ICER shows factors that have more
influence on this parameter. The probability of live birth
after the first and second embryo transfers and the
proportion of patients who had no more frozen embryos
available after non-achievement of live birth in the first or
second transfer influenced the comparative cost-effective-
ness of the two strategies. However, this approach is still
limited because only one parameter changes at a time. In
fact, all parameters could change simultaneously to any
value within their range. Therefore, PSA was used to
examine the change in ICER over 1000 trials in which all
parameters changed contemporaneously. This showed that
the probability of a corifollitropin alfa strategy being
accepted was 14.6%, whereas it would be rejected in up to
27.4% of scenarios. This means that the comparative cost-
effectiveness of the corifollitropin alfa and follitropin beta
strategies in the remaining scenarios (approximately 53%) is
less clear. In these settings, it would be interesting to know
how much a patient might be willing to pay for corifollitropin
alfa in order to achieve a 1% increase in the live birth rate;
this is an important area for future study.
When more than 40% of the total health expenditure is
required to be funded by patients as out-of-pocket pay-
ments, this is considered a source of financial health-related
catastrophe and impoverishment (Lee and Shaw, 2014). The
financial impact of fertility treatment is particularly
problematic in low- and middle-income countries where
these are fully self-funded (Dyer and Patel, 2012). In
contrast, most high-income countries have publicly fundedART options (Connolly et al., 2010). Therefore, in low- or
middle-income countries, the decision to use corifollitropin
alfa or follitropin beta for ovarian stimulation could have an
important influence on the rates of financial hardship and
treatment discontinuation.
In conclusion, in women aged 35–42 years weighing ≥50
kg undergoing one IVF/ICSI cycle in Vietnam, an ovarian
stimulation strategy based on follitropin beta 300 IU/day
was more cost-effective than a strategy based on
corifollitropin alfa 150 μg. ICER of corifollitropin alfa was
influenced to the greatest extent by the probability of live
birth after the first and second embryo transfers, and the
proportion of patients who had no more frozen embryos
available after non-achievement of live birth in the first or
second transfer. These factors need to be considered when
making a decision about the use of corifollitropin alfa versus
follitropin beta strategies. Furthermore, to confirm the
health economic impact of a corifollitropin alfa strategy
based on the level of out-of-pocket payments, it is important
to take average income per capita and WTP into account
before changing ART practice.
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.rbms.2020.01.002.
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